ARIAD Pharma (ARIA) Tops Q4 EPS by 17c, Offers Guidance

ARIAD Pharma (NASDAQ: ARIA) reported Q4 EPS of ($0.03), $0.17 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $66 million versus the consensus estimate of $39.5 million.

2015 Financial Guidance

• Net product revenues from sales of Iclusig are expected to be in the range of $130 million to $140 million. This guidance includes sales of Iclusig in the U.S., Europe, and other select countries where ARIAD has distributorships in place.
• R&D expenses are expected to be in the range of $185 million to $195 million, reflecting increased development activities for Iclusig, brigatinib, and AP32788, as well as ongoing discovery research efforts. Expenses related to Iclusig represent approximately 50% of total R&D expenses and include the three new planned trials to begin this year, as well as all ongoing trials. Expenses related to brigatinib represent approximately 35% of total R&D expenses and include the two ongoing trials and NDA-enabling pre-clinical studies.
• Selling, general and administrative expenses are expected to be in the range of $135 million to $145 million, of which approximately 55% represents U.S. and EU commercial operations and supporting activities for Iclusig.
• Non-cash expenses are expected to be in the range of $45 million to $50 million, consisting primarily of stock-based compensation and depreciation and amortization expenses.
• Cash and cash equivalents at December 31, 2015 is expected to be at least $200 million.

For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance